A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

Recruiting

Phase 3

mRNA COVID-19 VaccinesA Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

Sponsor:

Moderna

Code:

NCT05436834

Conditions

SARS-CoV-2

Eligibility Criteria

Sex: All

Age: 6 - 5

Healthy Volunteers: Accepted

Interventions

mRNA-1273.214

mRNA-1273.815

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by ModernaTX, Inc. on 2025-03-10.